Back to top
more

Owens & Minor (OMI)

(Real Time Quote from BATS)

$11.62 USD

11.62
384,150

-0.38 (-3.17%)

Updated Nov 5, 2024 12:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is Owens & Minor (OMI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout

by Zacks Equity Research

Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.

Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus

by Zacks Equity Research

Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.

Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis

by Zacks Equity Research

Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).

Here's Why You Should Hold on to Tandem Diabetes Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.

QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff

by Zacks Equity Research

QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.

Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm

by Zacks Equity Research

Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.

Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA

by Zacks Equity Research

This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.

LabCorp Partners With Medable to Expand Technology Ecosystem

by Zacks Equity Research

LabCorp (LH) expands technology ecosystem to accelerate the adoption of decentralized clinical trials by collaborating with Medable.

Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid

by Zacks Equity Research

Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.

Here's Why You Should Hold on to Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.

Teleflex (TFX) Rides on UroLift Sales Amid Coronavirus Mayhem

by Zacks Equity Research

NeoTract, the acquired business of Teleflex (TFX), continues to perform impressively.

IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis

by Zacks Equity Research

IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.

Henry Schein Sales Drop on Coronavirus Woes, Costs Rise

by Zacks Equity Research

Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.

Medtronic Gets FDA Nod for Guardian CGM's Android Version

by Zacks Equity Research

Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.

Should Value Investors Buy Owens & Minor (OMI) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Medtronic Launches Kyphon Cannula for Balloon Kyphoplasty

by Zacks Equity Research

Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.

Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.

ResMed (RMD) Launches Digital Tool for Remote Mask Selection

by Zacks Equity Research

Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.

    Neogen (NEOG) Introduces Upgraded Igenity Beef Genomic Profile

    by Zacks Equity Research

    Neogen (NEOG) looks to provide better technology and information to commercial beef producers to take better decisions for their profitability.

    Here's Why You Should Hold on to ResMed (RMD) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.

      Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem

      by Zacks Equity Research

      Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.

        Hologic's Second Molecular Test Gets EUA to Detect Coronavirus

        by Zacks Equity Research

        Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.

          Should Value Investors Buy Owens & Minor (OMI) Stock?

          by Zacks Equity Research

          Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

          Owens & Minor (OMI) Tops Q1 Earnings and Revenue Estimates

          by Zacks Equity Research

          Owens & Minor (OMI) delivered earnings and revenue surprises of 300.00% and 0.40%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?